About Avidity Biosciences, Inc.
https://www.aviditybiosciences.comAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
CEO
Sarah Boyce
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 151
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B of A Securities
Buy
Evercore ISI Group
Outperform
Wells Fargo
Overweight
Barclays
Overweight
Cantor Fitzgerald
Overweight
Raymond James
Market Perform
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
FMR LLC
Shares:21.59M
Value:$1.57B
JANUS HENDERSON GROUP PLC
Shares:14.52M
Value:$1.05B
VANGUARD GROUP INC
Shares:13.22M
Value:$958.96M
Summary
Showing Top 3 of 298
About Avidity Biosciences, Inc.
https://www.aviditybiosciences.comAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.47M ▲ | $201.28M ▲ | $-174.44M ▼ | -1.4K% ▲ | $-1.27 ▼ | $-173.39M ▼ |
| Q2-2025 | $3.85M ▲ | $36.86M ▼ | $-157.31M ▼ | -4.09K% ▲ | $-1.21 ▼ | $-170.33M ▼ |
| Q1-2025 | $1.57M ▼ | $133.09M ▲ | $-115.77M ▼ | -7.36K% ▼ | $-0.9 ▼ | $-130.73M ▼ |
| Q4-2024 | $2.97M ▲ | $123.96M ▲ | $-102.26M ▼ | -3.44K% ▲ | $-0.8 ▼ | $-120.25M ▼ |
| Q3-2024 | $2.34M | $100.47M | $-80.4M | -3.44K% | $-0.65 | $-97.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.88B ▲ | $2.13B ▲ | $247.94M ▲ | $1.89B ▲ |
| Q2-2025 | $1.18B ▼ | $1.37B ▼ | $176.26M ▲ | $1.19B ▼ |
| Q1-2025 | $1.38B ▼ | $1.46B ▼ | $130.35M ▼ | $1.33B ▼ |
| Q4-2024 | $1.5B ▼ | $1.56B ▼ | $138.94M ▲ | $1.42B ▼ |
| Q3-2024 | $1.59B | $1.64B | $137.39M | $1.5B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-174.44M ▼ | $-156.17M ▲ | $-587.93M ▼ | $850.37M ▲ | $106.25M ▲ | $-160.06M ▲ |
| Q2-2025 | $-157.31M ▼ | $-199.67M ▼ | $185.49M ▲ | $3.77M ▲ | $-10.29M ▼ | $-203.01M ▼ |
| Q1-2025 | $-115.77M ▼ | $-124.83M ▼ | $157.19M ▲ | $1.94M ▼ | $34.34M ▲ | $-128.58M ▼ |
| Q4-2024 | $-102.26M ▼ | $-99.87M ▼ | $-64.17M ▲ | $13.72M ▼ | $-150.32M ▲ | $-103.79M ▼ |
| Q3-2024 | $-80.4M | $-65.61M | $-482.41M | $342.46M | $-205.56M | $-67.32M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $10.00M ▲ |
CEO
Sarah Boyce
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 151
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B of A Securities
Buy
Evercore ISI Group
Outperform
Wells Fargo
Overweight
Barclays
Overweight
Cantor Fitzgerald
Overweight
Raymond James
Market Perform
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
FMR LLC
Shares:21.59M
Value:$1.57B
JANUS HENDERSON GROUP PLC
Shares:14.52M
Value:$1.05B
VANGUARD GROUP INC
Shares:13.22M
Value:$958.96M
Summary
Showing Top 3 of 298